Vice Chairman Lee Jae-yong Attends Completion Ceremony of Samsung Biologics Plant 4, the World's Largest Facility

Completion of the World's Largest Biofactory... Achieving Global No.1 CDMO Status

[Asia Economy Reporter Park Sun-mi] Samsung Electronics Vice Chairman Lee Jae-yong visited Samsung Biologics' Songdo campus in Yeonsu-gu, Incheon on the 11th to attend the completion ceremony of Biologics Plant 4, the world's largest biopharmaceutical production facility.

According to Samsung, Plant 4, which Vice Chairman Lee visited that day, is the world's largest biopharmaceutical production plant with a production capacity of 240,000 liters. It began operations this month. Samsung invested approximately 2 trillion KRW in the construction of Plant 4.

This is the first time in seven years since the groundbreaking ceremony of Samsung Biologics Plant 3 in 2015 that Vice Chairman Lee has visited the Songdo bio campus. With the operation of Plant 4, Samsung has secured a total biopharmaceutical production capacity of 420,000 liters, achieving the global No. 1 position in the Contract Development and Manufacturing Organization (CDMO) sector for biopharmaceuticals.

Samsung Biologics has achieved the world's No. 1 biopharmaceutical production capacity within 10 years of its launch through aggressive investment, and currently produces biopharmaceuticals on consignment for 12 of the world's top 20 pharmaceutical companies. In particular, with Plant 4, which has started partial operations, expected to be fully operational in 2023, production capacity will expand to a total of 600,000 liters, further solidifying its 'super-gap' advantage in the global bio CDMO market.

After personally inspecting the newly operational Plant 4, Vice Chairman Lee met separately with the management teams of Samsung Biologics and Samsung Bioepis to discuss mid- to long-term strategies for the CDMO and biosimilar businesses. Samsung continues aggressive investments to nurture bio as a 'future growth engine' comparable to semiconductors, while pursuing new growth drivers such as expanding the biosimilar pipeline.

In the CDMO sector, following the completion of Plant 4, Samsung plans to additionally construct Plant 5 and Plant 6, enhancing production technology and capabilities

to serve as a 'global biopharmaceutical production hub.'

Meanwhile, with the construction of Plant 4 fully utilizing the existing plant site, Samsung Biologics plans to establish a 'Second Bio Campus.' Samsung plans to invest 7.5 trillion KRW in the bio business over the next 10 years until 2032, creating an 110,000-pyeong (approximately 363,636 square meters) 'Second Campus,' where four additional plants will be built to complete the 'super-gap' in the bio sector. The Second Campus will also include an 'Open Innovation Center' to support the growth of domestic bio venture companies.

This content was produced with the assistance of AI translation services.